NUCRYST Pharmaceuticals has created a Board of Directors with a broad base of experience to guide business strategy and practices
Thomas E. Gardner - Barry M. Heck - Neil Carragher - Roger G.H. Downer, PhD - David Poorvin, PhD - Richard W. Zahn
Thomas E. Gardner became a director in May 2007 and was appointed Chairman, President & CEO of NUCRYST Pharmaceuticals in August 2007. Mr. Gardner previously served as CEO of a number of public and private companies including Songbird Hearing, Datamonitor, Base Ten Systems, and Access Health. From 1970 to 1995, Mr. Gardner held senior marketing and general management positions at Procter & Gamble, Johnson & Johnson, Simon & Schuster and IMS Health. He currently holds board seats at several privately held companies, including IntegriChain, VisiLED and Virium Pharmaceuticals. Mr. Gardner holds a BA in Economics and Mathematics from the University of St. Thomas.
Barry M. Heck has served as a director since incorporation. Mr. Heck has held a variety of senior executive positions at The Westaim Corporation over the past 10 years. Most recently he held the position of President and CEO of Westaim, playing a pivotal role in NUCRYST's 2005 Initial Public Offering. Mr. Heck also serves on the board of directors for several other public and private companies. He holds a law degree from the University of Alberta.
Neil Carragher became a director in December 2005. Mr. Carragher has been the Chairman of The Corporate Partnership Ltd., a management consulting group, for more than five years. Mr. Carragher is a director of Westaim and Agrium Inc. Mr. Carragher holds a B.Sc. from the University of Glasgow and a M.Sc. from the University of London.
Roger G.H. Downer, PhD became a director in December 2005. Dr. Downer has been the President and Vice-Chancellor of the University of Limerick, Ireland since 1998. Prior to that, Dr. Downer was President of the Asian Institute of Technology from 1996 to 1998. Dr. Downer is a director of Westaim. Dr. Downer holds a B.Sc. and M.Sc. from Queen’s University Belfast and a PhD from the University of Western Ontario.
David Poorvin, PhD became a director in May of 2006. Dr Poorvin has been a consultant for Poorvin Enterprises and served as Executive-in-Residence for Oxford Biosciences Partners. Dr. Poorvin is a director of Enanta Pharmaceuticals and Repros Therapeutics Inc. Dr. Poorvin held numerous senior management positions with the Schering-Plough Corporation, a global research-based company engaged in the discovery, development, manufacturing and marketing of pharmaceutical biotechnology products and health care products, including Vice President of Business Development Operations and Director of Cardiovascular Clinical Research. Dr. Poorvin holds a BA from Hunter College of the City University of New York, and PhD from Rutgers University.
Richard W. Zahn became a director in December 2005. From 1992 to 2003, Mr. Zahn held numerous senior management positions within the Schering-Plough Corporation, a global research-based company engaged in the discovery, development, manufacturing and marketing of pharmaceutical biotechnology products and health care products, including President of Schering Laboratories and Corporate Vice President of Schering-Plough Corporation. Schering Laboratories is the US prescription marketing arm for Schering-Plough. Mr. Zahn is a director of Norwood Abbey Ltd and Norwood Immunology Ltd. Mr. Zahn holds a BS in Business Administration from Kansas State Teachers College.